The Industry Pioneer Set to Dominate as CBD Goes Mainstream
Why Endexx is uniquely positioned to take this booming industry by storm
It seems like it’s everywhere…
Officially known as cannabidiol, most consumers refer to it as CBD. And whatever you call it, it is big business.
Growing from a small wellness niche to the mainstream has been no small feat for this industry, and the company we’re going to discuss today has played a major role in making that happen.
Consumers are turning to CBD products to treat an increasing array of conditions, and the market has responded to give them what they want. New CBD and cannabinoid wellness brands seem to be popping up every day, ready to capitalize on the trend.
Endexx Corp. (OTCMKTS:EDXC) is not one of these upstarts. In fact, a company like Endexx, selling premium CBD products since 2014, is an industry pioneer.
Back in the early days of CBD, Endexx founder and CEO Todd Davis saw a problem, and nobody else seemed to be doing anything about it. From these humble origins, Endexx and their stable of premium brands has risen to the top of this booming market that is set to explode in the years to come as CBD goes mainstream.
Producing high quality CBD products since 2014, Endexx is one of the oldest and most established players in this highly volatile space. They’ve got the experience, the leadership, and the team to dominate the future of the industry.
Scientifically consistent dosing
Inconsistent dosing was a serious problem in the early days of CBD, and it’s what inspired Todd Davis to start the company. Bringing a scientific approach to an industry that was anything but rigorous, Endexx delivers consistent CBD dosing across their entire product line.
Endexx distributes their products under different brand names targeting different segments of the market. Their flagship and longest running brand, CBD Unlimited, has been gaining consumer’s trust for years. They also produce Maggie’s Topicals, Phyto Bites pet CBD products, and their most recent addition, Blesswell, a line developed in partnership with DJ Khaled.
This isn’t some newcomer struggling for attention and shelf space. Endexx has nationwide distribution, including CVS and Walgreens, and can be found on the shelves of over 85,000 stores. They also sell their products directly online, and the Blesswell line specifically stands to benefit from exposure to over 20 million new social media followers. People want CBD, and Endexx is well positioned to be their brand of choice.
High profile partnerships
Endexx has partnered with DJ Khaled, record executive, and record producer DJ Khaled to create their new Blesswell line of CBD infused products. Khaled has over 20 million social followers, and this partnership is expected to drive significant revenue and brand awareness to a company that was already excellently positioned to ride the next wave of CBD. Solid revenues
With consistent year over year revenue growth, a popular and widely available product, and a reputation for quality, Endexx is the industry pioneer smart investors are turning to for exposure to the next wave of CBD.
An industry set to explode
Already a $2.8 billion industry in 2020, the CBD market is set to explode in the coming years, with experts forecasting a compound annual growth rate (CAGR) of 21.2% from 2021 to 2028. A rising tide lifts all boats, but in a volatile industry like this, the growth potential for a well positioned industry leader is even more promising.
A scientific approach to cannabinoid wellness
The Endexx story begins in the early days of the CBD industry, when things were in many ways still like the wild west. Products were inconsistent, companies came and went, often disappearing without a trace, and distribution left a lot to be desired.
Early CBD products, while usually effective, were produced under all sorts of conditions, and concentrations and proper dosage were often guesses at best.
Endexx founder and CEO Todd Davis knew there had to be a better way if the CBD industry was ever going to go mainstream and achieve the kind of growth we’re already seeing today.
With a biotech background stretching back to the early 90’s, Davis quickly identified that the young industry faced a major challenge, nobody knew how to measure and control dosage with a predictable outcome when utilizing hemp derived molecules.
Under the banner of their 2014 Hemp Pilot Program, Endexx recruited multiple doctors and their volunteer patients who helped define effective dosing ranges for each delivery system tested. All of Endexx’s product formulations to this day are based on the outcomes of this research, and further studies are ongoing.
This scientific approach was a first for an industry traditionally known for being anything but rigorous, and has carried Endexx from humble beginnings to the industry leader they are today.
CBD for every segment
Just as not all CBD companies are created equal, the same goes for CBD consumers. This is a growing $2.8 billion market, and that means a wide variety of use cases and preferences.
While some companies choose one market segment to focus on, Endexx has successfully diversified their brands and product lines to capture as many market segments as possible, all with the same unwavering commitment to quality and consistency.
CBD Unlimited, Endexx’s flagship brand since 2014, produces both topical and ingestible CBD products, and even includes a Green Value Line to capture more budget conscious consumers. CBD Unlimited benefits from years of name recognition and customer trust, making it a major force to be reckoned with.
Their Maggie’s brand is strictly topical, featuring mists and balms made with high end ingredients such as Arnica, MSM, and lemongrass, along with Edexx’s pure and consistent high quality CBD.
Phyto Bites is Endexx’s CBD line for pets, and includes CBD wellness drops and chews for pets of all sizes. It may surprise some readers to hear that the global pet CBD market alone was valued at $125 million in 2020 and is expected to grow at a CAGR of 58.9% from 2021 to 2028.
In their most recent addition to the product line, Endexx has partnered with superstar DJ Khaled to create Blesswell, a line of CBD enhanced men’s grooming products focusing on skin and beard care, the Blesswell line is set to capture another growing segment of the CBD market, and will benefit immensely from Khaled’s name recognition and 20+ million social media followers.
Available when you need it
One of the challenges of the early CBD market was availability. In most cases, products had to be ordered and shipped, with days between the purchase and initial use of the product.
These days it seems that CBD is available on every corner, and next time you see it at your local store, you may want to look a bit closer. With nationwide distribution to over 85,000 stores, there’s a good chance that CBD product you see at CVS or Walmart was made by Endexx.
In addition to their expansive and growing retail presence, Endexx sells their products online through the CBD Unlimited storefront, among others, and will soon benefit from the exposure brought from their Blesswell partnership with DJ Khaled.
Consumers have more choices than ever in CBD, and no matter what they’re looking for, Endexx has a brand positioned to give them exactly what they need and when they need it.
Experience that delivers results
7 years is eons in the CBD industry, and the fact that a company has survived this long tells you something. Many smaller players have come and gone, and even more will vanish as CBD goes mainstream and established players seize the rewards of the next wave of growth.
Endexx has the seniority, the experience, and the team to ensure victory as more and more people turn to CBD for their health and wellness.
As we’ve mentioned, CEO Todd Davis comes from an extensive biotech background, and the entire company was founded with science, consistency, and quality in mind. On top of this, the team at Endexx has seen again and again the benefits these products provide for their customers, and their mission is to “…improve quality of life with the genuine concern of the Well-Being of others.”
All employees at Endexx are shareholders, which means their interests are aligned with yours as an investor. You can trust that the decisions they make will benefit both the consumer and the company, and by extension the investors. This structure has paid off handsomely, catapulting Endexx to the top of a very competitive market and positioning them to win in the years to come.
What you need to know as an investor
One thing is absolutely clear; CBD wellness isn’t going anywhere. Consumers have spoken, and they want CBD. For themselves, in topical and ingestible formats, and even for their pets. From the high end to the low end of the market, sales show no sign of slowing, and this $2.8 billion is set to go to the moon over the next few years as the mainstream segments of the market jump on board.
This makes right now a great time to add exposure to CBD to your portfolio, and experts agree that at under 6 cents per share at the time of this writing, Endexx is a seriously undervalued opportunity.
They have the benefit and the hindsight that only comes from being an industry pioneer. They’ve seen it all, survived the turmoil of the early days, and developed a product and a market position that sets them up squarely to benefit from the next wave of CBD growth.
Endexx has CBD products for almost everyone, even pets, and their recent Blesswell partnership with superstar DJ Khaled adds over 20 million potential customers to their sphere of influence. Whether you decide to add a position in Endexx to your portfolio today or not, you can learn more about everything they’re working on at Endexx.com.
Mr. Hasty was formerly Regional Vice President of a Fortune 500 retail Pharmacy bringing 40 years of expertise.
Timothy Hayes, R.Ph., Speciality Advisor
Mr. Hayes has been a Pharmacist for more than 50 years and has owned and operated pharmacies for more than 40 years.
Who are we and what do we do?
We are paid advertisers, also known as stock touts or stock promoters, who disseminate favorable information (the “Information”) about publicly traded companies (the “Profiled Issuers”).
How is the Information published?
We publish the Information on our Website, in newsletters, audio services, live interviews, featured “research” reports, on message boards and in email communications for specific time periods that are agreed upon between us and the Profiled Issuer or third party paying us.
Our publication of the Information is known as a “Campaign”.
Will everyone receive the Information at the same time?
No. The Information may be sent to potential investors at different times that are minutes, hours, days or even weeks apart.
How is a potential investor impacted if he receives the Information later than other investors?
Typically, the trading volume and price of a Profiled Issuer’s securities increases after the Information is provided to the first group of investors. Therefore, the later an investor receives the Information, the more likely it is that he will suffer increased trading losses if he purchases the securities of a Profiled Issuer.
What will happen to the shares that we hold during the Campaign?
We will sell the shares we hold while we tell investors to purchase during the Campaign.
What will happen when the Campaign ends?
Most, if not all, of the Profiled Issuers are penny stocks that are illiquid and whose securities are subject to wide fluctuations in trading price and volume. During the Campaign the trading volume and price of the securities of each Profiled Issuer will likely increase significantly. When the Campaign ends, the volume and price of the Profiled Issuer will likely decrease dramatically. As a result, investors who purchase during the Campaign and hold shares of the Profiled Issuer when the Campaign ends will probably lose most, if not all, of their investment.
Why do we publish only favorable Information?
We only publish favorable information because we are compensated to publish only favorable information.
Why don’t we publish negative Information?
We don’t publish negative information because we are not paid to publish negative information. We are paid to publish only favorable information.
Is the Information complete, accurate, truthful or reliable?
No. The Information is a snapshot that provides only positive information about the Profiled Issuers. The Information consists of only positive content. We do not and will not publish any negative information about the Profiled Issuers; accordingly, investors should consider the Information to be one-sided and not balanced, complete, accurate, truthful or reliable.
What we do not do?
We do not publish negative information about the Profiled Issuers. We do not verify or confirm any portion of the Information. We do not conduct any due diligence, nor do we research any aspect of the Information including the completeness, accuracy, truthfulness or reliability of the Information. We do not review the Profiled Issuers’ financial condition, operations, business model, management or risks involved in the Profiled Issuer’s business or an investment in a Profiled Issuer’s securities.
Where does the Information come from?
The Information is provided to us by the Profiled Issuers and/or the person who hires us. We may also obtain the Information from publicly available sources such as the OTC Markets, Google, NASDAQ, NYSE, the Securities and Exchange Commission’s Edgar database or other available public sources.
If we say we make “stock picks,” are those picks our own?
No, they are not. We are compensated to advertise the securities we are told to advertise.
What will happen if an investor relies on the Information?
If an investor relies on the Information in making an investment decision it is highly probable that the investor will lose most, if not all, of his or her investment. Investors should not rely on the Information to make an investment decision.
Who pays us to publish the Information?
The source of our compensation varies depending upon the particular circumstances of the Campaign. We are compensated by the Profiled Issuers, third party shareholders and other parties related to the Profiled Issuers such as officers and/or directors who will derive a financial or other benefit from an increase in the trading price and/or volume of a Profiled Issuer’s securities.
The nature and amount of compensation we receive for publishing the Information about each Profiled Issuer and our ownership of each Profiled Issuer is set forth below under the heading captioned, “What we are compensated”.
What warranties do we make about the Information?
None. We make no warranty or representation about the Information, including its completeness, accuracy, truthfulness or reliability and we disclaim, expressly and implicitly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable and as such, your use of the Information is at your own risk. The Information is provided as is without limitation.
What we are not.
We are not and do not act in the capacity of any of the following; as such, you should not construe our activities as involving any of the following:
An independent adviser or consultant;
A fortune teller;
An investment adviser or an entity engaging in activities that would be deemed to be providing investment advice that requires registration either at the federal or state level;
A broker-dealer or an individual acting in the capacity of a registered representative or broker;
A stock picker;
A securities trading expert;
A securities researcher or analyst;
A financial planner or one who engages in financial planning;
A provider of stock recommendations;
A provider of advice about buy, sell or hold recommendations as to specific securities; or
An agent offering or securities for sale or soliciting their purchase.
Are risks in this disclaimer the only risks investors should be aware of?
No. There are numerous risks associated with each Profiled Issuer and investors should undertake a full review of each Profiled Issuer with the assistance of their financial, legal, and tax advisers prior to purchasing the securities of any Profiled Issuer.
What conflicts of interest do we have in publishing the Information?
We are not objective or independent and have multiple conflicts of interest. The Profiled Issuers and parties hiring us have conflicts of interest.
What will happen to the shares that we hold during the Campaign?
We will sell the shares we hold while we tell investors to purchase.
Our publication of the Information involves actual and material conflicts of interest including but not limited to the following:
We receive monetary and/or securities compensation in exchange for publishing the (favorable) Information about the Profiled Issuers;
We do not publish any negative information whatsoever about the Profiled Issuers;
We may own a Profiled Issuer’s securities that we acquired from the Profiled Issuer, third parties or from our own open market purchases before, during or after the Campaign and we may sell these securities during the Campaign while publishing the (favorable) information that instructs investors to purchase. Our selling of a Profiled Issuer’s securities will likely cause investors to suffer losses;
A short time after we acquire a Profiled Issuer’s securities, we may publish the (favorable) Information about the Profiled Issuer advising others, including you, to purchase; and while doing so, we may sell the Profiled Issuer’s securities we acquired during our public dissemination of the Information causing us to profit while you suffer a loss;
Parties holding a Profiled Issuer’s securities, including those who engage our services and/or compensate us, will sell their shares of the Profiled Issuer while we are publishing the (favorable) Information.
Who is responsible if an investor relies on the Information?
The investor. We are not responsible or liable for any person’s use of the Information or any success or failure that is directly or indirectly related to such person’s use of the Information because we have specifically stated that the information is not reliable and should not be relied upon for any purpose. We are not responsible for omissions or errors in the Information, and we are not responsible for actions taken by any person who relies upon the Information.
What do we urge potential investors to do?
We urge Investors to conduct their own in-depth investigation of the Profiled Issuers with the assistance of their legal, tax and investment advisers. An investor’s review of the Information should include but not be limited to the Profiled Issuer’s financial condition, operations, management, products or services, trends in the industry and risks that may be material to the profiled Issuer’s business and other information he and his advisers deem material to an investment decision. An investor’s review should include, but not be limited to a review of available public sources and information received directly from the Profiled Issuers or from websites such as Google, OTC Markets, NASDAQ, NYSE, www.sec.gov or other available public sources.
Why is this Disclaimer being provided?
We are providing you with this disclaimer because we are publishing advertisements about penny stocks. Because we are paid to disseminate the Information to the public about securities, we are required by the securities laws including Section 10(b) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 thereunder, and Section 17(b) of the Securities Act of 1933, as amended (the “Securities Act”), to specifically disclose our compensation as well as other important information, This information includes that we may hold, as well as purchase and sell, the securities of a Profiled Issuer before, during and after we publish favorable Information about the Profiled Issuer. We may urge investors to purchase the securities of a Profiled Issuer while we sell our own shares.
The anti-fraud provisions of federal and state securities laws require us to inform you that we may engage in buying and selling of Profiled Issuer’s securities before, during and after the Campaigns.What are other risks that investors should be aware of?
Any investment in the Profiled Issuers involves a high degree of risk and uncertainty. The securities may be subject to extreme volume and price volatility, especially during the Campaigns. Favorable past performance of a Profiled Issuer does not guarantee future results. If you purchase the securities of the Profiled Issuers, you should be prepared to lose your entire investment. Some of the risks involved in purchasing securities of the Profiled Issuers include, but are not limited to the risks stated below.
We do not endorse, independently verify or assert the truthfulness, completeness, accuracy or reliability of the Information. We conduct no due diligence or investigation whatsoever of the Information or the Profiled Issuers and we do not receive any verification from the Profiled Issuer regarding the Information we disseminate.
If we publish any percentage gain of a Profiled Issuer from the previous day close in the Information, it is not and should not be construed as an indication that the future stock price or future operational results will reflect gains or otherwise prove to be advantageous to your investment.
The Information may contain statements asserting that a Profiled Issuer’s stock price has increased over a certain period of time which may reflect an arbitrary period of time, and is not predictive or of any analytical quality; as such, you should not rely upon the (favorable) Information in your analysis of the present or future potential of a Profiled Issuer or its securities.
The Information should not be interpreted in any way, shape, form or manner whatsoever as an indication of the Profiled Issuer’s future stock price or future financial performance.
You may encounter difficulties determining what, if any, portions of the Information are material or non-material, making it all the more imperative that you conduct your own independent investigation of the Profiled Issuer and its securities with the assistance of your legal, tax and financial advisor.
We or other stock promoters may receive free trading shares as compensation or we may acquire such shares in open market transactions before and during the Campaigns, and we may sell the shares we acquire at any time, even during the Campaigns while publishing the Favorable Information. When we sell the shares of the Profiled Issuers that we hold, the price at which investors can sell their shares will dramatically decrease and will likely cause investors to suffer trading losses.
We may sell securities of the Profiled Issuers for less than target prices set forth in the Information, and we may profit by selling our securities during the Campaigns while investors encounter losses.
When we acquire, purchase or sell the securities of the Profiled Issuers, it may (a) cause significant volatility in the Profiled Issuer’s securities; (b) cause temporary but unrealistic increases in volume and price of the Profiled Issuer’s securities; (c) if selling, cause the Profiled Issuer’s stock price to decline dramatically; and (d) permit us to make substantial profits while investors who purchase during the Campaign experience significant losses.
The securities of the Profiled Issuers are high risk, unstable, unpredictable and illiquid which may make it difficult for investors to sell their securities of the Profiled Issuers.
If we are compensated in improperly free trading securities of the Profiled Issuers, either directly or indirectly from persons who claim to be non-affiliates of such Profiled Issuer, we and the Profiled Issuer or third party could be subject to SEC Enforcement Action, including allegations of an illegal distribution in violation of Section 5(a) and 5(c) of the Securities Act.
We may hire third party service providers and stock promoters to electronically disseminate live news regarding the Profiled Issuers, yet we have no control over the content of and do not verify the information that the Profiled Issuers and/or third party service providers publish. These third party service providers are likely compensated for providing positive information about the Issuer and fail to disclose their compensation to you.
If a Profiled Issuer is an SEC reporting company, it could be delinquent (not current) in its periodic reporting obligations (i.e., in its quarterly and annual reports), or if it is an OTC Markets Pink Sheet quoted company, it may be delinquent in its Pink Sheet reporting obligations, which may result in OTC Markets posting a negative legend pertaining to the Profiled Issuer at www.otcmarkets.com, as follows: (i) “Limited Information” for companies with financial reporting problems, economic distress, or that are unwilling to file required reports with the Pink Sheets; (ii) “No Information,” which characterizes companies that are unable or unwilling to provide any disclosure to the public markets, to the SEC or the Pink Sheets; and (iii) “Caveat Emptor,” signifying buyers should be aware that there is a public interest concern associated with a company’s illegal spam campaign, questionable stock promotion, known investigation of a company’s fraudulent activity or its insiders, regulatory suspensions or disruptive corporate actions.
If the Information states that a Profiled Issuer’s securities are consistent with the future economic trends or even if your independent research indicates that, you should be aware that economic trends have their own limitations, including: (a) that economic trends or predictions may be speculative; (b) consumers, producers, investors, borrowers, lenders and government may react in unforeseen ways and be affected by behavioral biases that we are unable to predict; (c) human and social factors may outweigh future economic trends that we state may or will occur; (d) clear cut economic predictions have their limitations in that they do not account for the fundamental uncertainty in economic life, as well as ordinary life; (e) economic trends may be disrupted by sudden jumps, disruptions or other factors that are not accounted for in economic trends analysis; in other words, past or present data predicting future economic trends may become irrelevant in light of new circumstances and situations in which uncertainty becomes reality rather than predicted economic outcome; or (f) if the trend predicted involves a single result, it ignores other scenarios that may be crucial to make a decision in the event of unknown contingencies.
The Information is presented only as a brief snapshot of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities. You should consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.govwww.sec.gov, www.otcmarkets.com or other electronic media, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the OTCMarkets.com; (c) obtaining and reviewing publicly available information contained in commonly known search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.org. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and the OTC Markets and/or have negative legends and designations at otcmarkets.com.
What we were paid to advertise the Profiled Issuers.
The details of our compensation and the period of the Campaign is set forth below.
Name of Issuer & Ticker Symbol - Endexx Corp. (EDXC)
Amount & Form of Compensation - $300,000.00 in Restricted Common Stock
Who Paid for the Campaign & Position with Company if any - Endexx Corp. (EDXC)
Period of Campaign - 10/26/2021 - 10/26/2022
What securities of the Profiled Issuers do we hold?
The positions we hold of the Profiled Issuer are set forth below. We plan to sell these securities during the Campaign.
Name of Issuer & Ticker Symbol - Endexx Corp. (EDXC)
Number of Shares We or our Affiliates Hold - 6,211,180
. To find out more, read our